Disitamab Vedotin (RC48-ADC) in Breast Cancer

A Study of RC48-ADC for the Treatment of HER2-expressing Gynecological Malignancies

NCT04965519 ·Status: RECRUITING ·Phase: PHASE2

Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast Cancer

NCT03907800 ·Status: UNKNOWN ·Phase: PHASE2

A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

NCT03500380 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3

A Study of RC48-ADC in Subjects With Advanced Breast Cancer

NCT03052634 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)

NCT05904964 ·Status: RECRUITING ·Phase: PHASE3

RC48 for Neoadjuvant Chemotherapy of HER2 Positive Breast Cancer

NCT05134519 ·Status: UNKNOWN ·Phase: PHASE2

A Phase II Clinical Study of Treatment With Disitamb Vedotin Plus Pyrotinib in HER2-positive Early Breast Cancer

NCT06001086 ·Status: RECRUITING ·Phase: PHASE2

RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

NCT07065435 ·Status: RECRUITING ·Phase: PHASE2

JS207 Combination Therapy in Triple-negative Breast Cancer

NCT07045311 ·Status: RECRUITING ·Phase: PHASE2

Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy

NCT04437160 ·Status: RECRUITING ·Phase: PHASE2

The Rechallenge of ADCs in MBC Patients

NCT05571618 ·Status: ACTIVE_NOT_RECRUITING

B003 in Patients With HER2-positive Recurrent or Metastatic Breast Cancer

NCT03953833 ·Status: COMPLETED ·Phase: PHASE1

Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer

NCT04136782 ·Status: RECRUITING ·Phase: PHASE4

Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer

NCT03055312 ·Status: TERMINATED ·Phase: PHASE3

A Phase II Study of Triple-negative Breast Cancer Brain Metastases.

NCT04303988 ·Status: RECRUITING ·Phase: PHASE2

A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast

NCT04481763 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer

NCT07150767 ·Status: WITHDRAWN ·Phase: PHASE1

RWS of Paclitaxel Liposome Combined With Anti-HER-2 Monoclonal Antibody

NCT06481553 ·Status: ACTIVE_NOT_RECRUITING

A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)

NCT07208149 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

AR-inhibitor Bicalutamide in Treating Patients With TNBC

NCT02353988 ·Status: UNKNOWN ·Phase: PHASE2

DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer

NCT05334810 ·Status: UNKNOWN ·Phase: PHASE2

Tumor Response Time of Palbociclib in Combination With AI in Real-world Chinese Patients

NCT04858997 ·Status: UNKNOWN ·Phase: PHASE2

Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer

NCT05519059 ·Status: COMPLETED ·Phase: PHASE1

A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast Cancer

NCT05629949 ·Status: COMPLETED ·Phase: PHASE3

A Study of A166 in Patients With Advanced Solid Malignant Tumors

NCT05311397 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1